ClinicalTrials.gg
CompletedNCT07572188Updated Nov 12, 2026

Diabetic Foot Self Care

An observational study in Diabetic Foot Ulcer, Self Care and Nursing Care, sponsored by Namik Kemal University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Namik Kemal University · Observational

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
202
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Diabetic Foot with a site in Turkey — 14 open to participants now, 18 under way, none of them phase 3. Diabetic Foot · Turkey.

Started
2023
with 8 others
Observational
9 of 48
2 open now
Registered
44th of 48
by date

Among the 48 studies in Diabetic Foot with a site in Turkey, this one is one of 9 that started in 2023, is one of 9 observational ones, and was the 44th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

14 of the 48 studies in Diabetic Foot with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Diabetic Foot with a site in Turkey, or all of them as a file.
02

Study summary

The scale, whose validity and reliability were examined in the study, consists of 26 items. The study sample consisted of 202 individuals with diabetes. Data were collected through face-to-face interviews, with approximately 30 minutes allocated to each individual. The study sample included individuals over 18 years of age, diagnosed with diabetes, who spoke, read, and wrote Turkish, and who provided verbal and written consent to participate in the study. Individuals with serious psychiatric diagnoses, cognitive problems that would impede self-expression, and those who wished to withdraw from the study at any stage were excluded from the study sample.

Read the detailed description

The scale, whose validity and reliability were examined in the study, consists of 26 items. The study sample consisted of 202 individuals with diabetes. Data were collected through face-to-face interviews, with approximately 30 minutes allocated to each individual. The study sample included individuals over 18 years of age, diagnosed with diabetes, who spoke, read, and wrote Turkish, and who provided verbal and written consent to participate in the study. Individuals with serious psychiatric diagnoses, cognitive problems that would impede self-expression, and those who wished to withdraw from the study at any stage were excluded from the study sample.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Self Care
  • Nursing Care

Browse trials for

Keywords

  • diabetic foot
  • self care
  • nursing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study sample consisted of 202 individuals with diabetes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • speaking Turkish
  • over 18 years old
  • Not having a serious psychiatric diagnosis
  • Giving written consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • severe visual or auditory problems
  • who did not volunteer to participate in the study
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
202 participants (actual)
Patient registry
No

Interventions

  • BehavioralSelf-Care Tool for Diabetic Foot Prevention

    This study examines the validity and reliability of the Turkish version of the Self-Care Tool for Diabetic Foot Prevention, developed according to the theory of Riegel et al.

06

What researchers measure

Primary outcomes

  1. Self-Care Tool for Diabetic Foot Prevention

    This tool consists of 26 items and 3 sub-dimensions, evaluated on a 5-point Likert scale. The sub-dimensions are based on Riegel et al.'s moderate self-care theory. These sub-dimensions are maintaining self-care, monitoring self-care, and managing self-care. The maintaining self-care sub-dimension (10 items) consists of recommendations from healthcare professionals regarding daily foot care and diabetes-related practices to prevent diabetic foot ulcers. The monitoring self-care sub-dimension (9 items) includes behaviors related to monitoring early and initial signs of foot injuries. The managing self-care sub-dimension (7 items) consists of recommendations for practices aimed at eliminating risk factors for foot health.

    Time frame: 21 month

07

Study locations

1 site
  • Tekirdag Namık Kemal University
    Tekirdağ, Suleymanpasa 59000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2023 to primary completion in Oct 2024, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2024 → Oct 2024 and completion Dec 2024 → Oct 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 7, 2026
StartActual
Apr 1, 2023
Primary completionActual
Oct 1, 2024was Dec 2024
CompletionActual
Oct 1, 2024was Dec 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2024→Oct 1, 2024
Nov 12, 2026
Study completion
Dec 1, 2024→Oct 1, 2024
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 1, 2024→Oct 1, 2024
    Study completion Dec 1, 2024→Oct 1, 2024

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07572188
Lead sponsor
Namik Kemal University
Responsible party
Cagla AVCU (Research Assisstant Dr., Namik Kemal University) — Principal investigator
First posted
May 7, 2026
Start date
Apr 1, 2023
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion